Pre-Exposure Prophylaxis and HIV Incidence

Mann Samuel ()
Additional contact information
Mann Samuel: RAND Corporation, Arlington, USA

The B.E. Journal of Economic Analysis & Policy, 2023, vol. 23, issue 4, 1163-1173

Abstract: Pre-Exposure Prophylaxis (PrEP) is a drug that, as demonstrated in clinical trials, when taken makes the user virtually immune to HIV. This has led to numerous countries making the drug available, but little is known about the population level effects of PrEP. Using panel data from 40 European countries I study the effect of countries adopting WHO recommendations to make PrEP available to citizens. I demonstrate that PrEP availability leads to around 15–20 % fewer new HIV infections. My results indicate that PrEP can be an effective tool in reducing HIV incidence.

Keywords: pre-exposure prophylaxis; PrEP; HIV; sexual health (search for similar items in EconPapers)
JEL-codes: I1 I18 (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1515/bejeap-2023-0087 (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bpj:bejeap:v:23:y:2023:i:4:p:1163-1173:n:8

Ordering information: This journal article can be ordered from
https://www.degruyter.com/journal/key/bejeap/html

DOI: 10.1515/bejeap-2023-0087

Access Statistics for this article

The B.E. Journal of Economic Analysis & Policy is currently edited by Hendrik Jürges and Sandra Ludwig

More articles in The B.E. Journal of Economic Analysis & Policy from De Gruyter
Bibliographic data for series maintained by Peter Golla ().